Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Interest & Investment Income (2016 - 2025)

Viking Therapeutics' Interest & Investment Income history spans 12 years, with the latest figure at $7.0 million for Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 35.13% year-over-year to $7.0 million; the TTM value through Dec 2025 reached $33.7 million, down 17.67%, while the annual FY2025 figure was $33.7 million, 17.67% down from the prior year.
  • Interest & Investment Income for Q4 2025 was $7.0 million at Viking Therapeutics, down from $7.8 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $11.8 million in Q2 2024 and bottomed at $125000.0 in Q3 2021.
  • The 5-year median for Interest & Investment Income is $4.6 million (2023), against an average of $4.6 million.
  • The largest annual shift saw Interest & Investment Income plummeted 82.6% in 2021 before it surged 1697.23% in 2023.
  • A 5-year view of Interest & Investment Income shows it stood at $159000.0 in 2021, then surged by 360.38% to $732000.0 in 2022, then skyrocketed by 542.9% to $4.7 million in 2023, then soared by 130.43% to $10.8 million in 2024, then crashed by 35.13% to $7.0 million in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Interest & Investment Income are $7.0 million (Q4 2025), $7.8 million (Q3 2025), and $9.0 million (Q2 2025).